右佐匹克隆与氯硝西泮辅助治疗精神分裂症睡眠障碍对照研究

Comparative study between eszopiclone and clonazepam in adjuvant treatment of sleep disorders of schizophrenia

目的探讨右佐匹克隆辅助治疗精神分裂症睡眠障碍的疗效及安全性。方法 91例伴睡眠障碍的精神分裂症患者(均统一服用阿立哌唑10～20mg·d^(-1))随机分成2组,分别口服右佐匹克隆3～6mg·d^(-1)(n=45)或氯硝西泮2～4mg·d^(-1)(n=46),采用匹兹堡睡眠质量指数(PSQI)、阳性和阴性症状量表(PANSS)、副反应量表(TESS)评定疗效和安全性;观察3wk。结果 2组各完成43例。治疗3wk后,2组睡眠时间均显著延长,PSQI评分和PANSS评分显著下降(均P<0.01),2组间疗效无显著差异(P>0.05);右佐匹克隆组日间功能障碍的改善显著优于氯硝西泮组[(1.2±0.9)分vs.(1.6±0.7)分,P<0.05];2组TESS评分无显著差异(P>0.05),右佐匹克隆组嗜睡、头昏的发生率显著少于氯硝西泮组(P<0.05)。结论右佐匹克隆辅助治疗精神分裂症睡眠障碍疗效显著,安全性优于氯硝西泮。

AIM To detect the clinical efficacy and safety of eszopiclone in the adjuvant treatment of sleep disorders of schizophrenia. METHODS Ninety-one schizophrenic patients with sleep disorders, who received aripiprazole 10 - 20 mg·d^-1 were divided into two groups, 45 for eszopiclone （3 - 6 mg·d^-1） group and 46 for clonazepam （2 - 4 mg·d^-1） group. PSQI, PANSS and TESS were used to evaluate the efficacy and safety of the 3-week treatment. RESULTS The two groups completed 43 patients for each. By the end of the traatment, the sleep duratioo increased and the PSQI scores and PANSS scores of the two groups decreased signifieaotly （all P 〈 0.01 ） , and there was no significant difference in the overall efficacy betweeq the two groups （P 〉 0.05） , But the ezopiclone group had better effect on treating daytime dysfunciton than the clonazepam group [（ 1.2 ± 0.9） vs. （1.6 ± 0.7）, P 〈 0.05]. There was no sigpificant diffence in the TESS scores between the two groups （P 〉 0.05） , but the. incidence rates of somnolence and dizziness in the eszopielone group were lower tban that of the clonazepam group （P 〈 0.05） . CONCLUSION .Eszopicloriclone has significant affects on the treatment of sleep disorders of schizophrenia, and it is more secure than cloazepam.